拉喹莫德 T6561

Product Introduction
Bioactivity


英文名: Laquinimod

描述: Laquinimod (LAQ) 是一种免疫调节剂，可预防中枢神经系统的神经变性和炎症。

细胞实验: The peripheral blood mononuclear cells (PBMC) are incubated with Laquinimod for 24 hours. Cell viability is measured on total PBMC by propidium iodide (PI) staining using an automated cell counter. Protein expression level is assessed in PBMC samples by Western blot using anti-HLA-DQA/DQB monoclonal antibodies.(Only for Reference)

体外活性: Laquinimod treatment at 0.1-1 μM does not affect the viability of peripheral blood mononuclear cells (PBMC). By performing the large-scale gene expression microarray analysis in PBMC from healthy subjects or relapsing-remitting multiple sclerosis (RRMS) patients, Laquinimod is shown to induce suppression of genes related to antigen presentation and corresponding inflammatory pathways. Laquinimod induces activation of Th2 response in CD14+ and CD4+ cells and suppression of proliferation in CD8+ cells. Laquinimod displays significant effects on immune modulation related to the suppression of antigen presenting mechanism followed by a decrease of chemotaxis and adhesion, and exhibits potent anti-inflammatory potency through the suppression of the NF-κB pathway that concordantly leads to the activation of apoptosis of immuno-competent cells. [5]

体内活性: Administration of Laquinimod (0.16-16 mg/kg/day) dose-dependently inhibits the incidence of experimental autoimmune neuritis (EAN) in Lewis rats, ameliorates Clinicalal signs and inhibits P0 peptide 180-199-specific T cell responses as well as the inflammation and demyelination in the peripheral nerves, suggesting that Laquinimod may mediate its effects by regulation of Th1/Th2 cytokine balance. [1] Laquinimod significantly inhibits the development of murine acute experimental autoimmune encephalomyelitis (EAE), being approximately 20 times more potent than the immunomodulator roquinimex. [2] Laquinimod treatment inhibits the development of experimental autoimmune encephalomyelitis (EAE) in the Lewis rat in a dose-dependent manner, and shows better disease inhibitory effects as compared to roquinimex (Linomide). [3] Laquinimod potently inhibits the development of chronic experimental autoimmune encephalomyelitis (chEAE) in IFN-beta k.o. mice and wild type mice. [4] Laquinimod reduces Clinicalal signs, inflammation, and demyelination in C57BL/6 mice with active EAE induced with MOG(35-55) peptide, and down-regulates VLA-4-mediated adhesiveness and pro-inflammatory cytokines such as IL-17. [6] The study of Laquinimod in the mice model of EAE using a conditional BDNF knockout strain lacking BDNF expression in myeloid cells and T cells (LLF mice) indicates Laquinimod also modulates autoimmune demyelination via induction of brain-derived neurotrophic factor (BDNF). [7]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: Ethanol : 1 mg/mL (2.8 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 57 mg/mL (159.8 mM)


关键字: inhibit | multiple sclerosis | relapsing remitting | Laquinimod | carboxamide | Nuclear factor-kappaB | Apoptosis | Inhibitor | ABR 215062 | Nuclear factor-κB | immunomodulator | ABR215062 | chronic progressive | neurodegenerative disease | inflammation | NF-κB | Orally | neurodegeneration

相关产品: Fedratinib | DB1976 dihydrochloride | Thiamine hydrochloride | Euscaphic acid | ON1231320 | Minodronic acid | OSI-930 | FB23-2 | MDK83190 | Tangeretin

相关库: Anti-Aging Compound Library | Anti-Neurodegenerative Disease Compound Library | Drug Repurposing Compound Library | Anti-Liver Cancer Compound Library | Anti-Cancer Drug Library | Anti-Lung Cancer Compound Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library | Apoptosis Compound Library | EMA Approved Drug Library

拉喹莫德 T6561信息由TargetMol中国为您提供，如您想了解更多关于拉喹莫德 T6561报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途